Loading…
Loading…
EQUITY / NASDAQ · XNCM
Medicus Pharma Ltd.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.1626 USD · 0.9938%
Observed: Oct 2, 2026, 11:42 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 0.161 USD · Volume 1,038,968
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -11,478,789 USD | -6,016,088 USD | — |
| Net income | -11,617,705 USD | -6,176,084 USD | — |
| Cash and cash equivalents | 15,174,128 USD | — | — |
| Total liabilities | 28,841,149 USD | — | — |
| Total equity | -1,763,651 USD | 3,248,710 USD | -154.29% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 15,174,128 USD | — | — | 8,705,218 USD | 8,705,218 USD | 8,662,091 USD | — | — |
| Net incomeIncome statement | -11,617,705 USD | -20,659,848 USD | -9,042,311 USD | — | -47,281,513 USD | -20,935,753 USD | -32,214,245 USD | -6,176,084 USD |
| Operating profitIncome statement | -11,478,789 USD | -20,075,866 USD | — | — | -34,359,302 USD | -15 USD | -26,568,702 USD | -6,016,088 USD |
| Total assetsBalance sheet | 27,116,185 USD | — | — | 10,061,377 USD | 10,061,377 USD | 9,977,661 USD | — | — |
| Total equityBalance sheet | -1,763,651 USD | — | 1,427,894 USD | -67,554 USD | -67,554 USD | -910,126 USD | — | 3,248,710 USD |
| Total liabilitiesBalance sheet | 28,841,149 USD | — | — | 10,024,066 USD | 10,024,066 USD | 10,782,551 USD | — | — |
| Financing cash flowCash flow statement | — | 32,354,942 USD | — | — | 31,939,785 USD | — | 25,286,315 USD | — |
| Operating cash flowCash flow statement | — | -15,953,129 USD | — | — | -22,776,769 USD | — | -16,167,654 USD | — |
| Investing cash flowCash flow statement | — | — | — | — | -4,619,152 USD | — | -4,619,152 USD | — |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 03/25/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/12/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.